New drug combo shows promise for inherited breast cancer
NCT ID NCT03641755
First seen Dec 12, 2025 · Last updated Jun 11, 2026 · Updated 26 times
Summary
This early-phase study tests a combination of two drugs, olaparib and sapacitabine, in people with breast cancer that has spread and who have a BRCA gene mutation. The main goals are to find the safest dose and see if the combination shrinks tumors. About 10 participants are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Broad Institute of MIT
Cambridge, Massachusetts, 02142, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.